{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:36:06Z","timestamp":1780443366182,"version":"3.54.1"},"reference-count":62,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T00:00:00Z","timestamp":1187827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2007,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>The molecular classification system categorizes invasive breast carcinomas according to their key driving biomarkers. In the current study, the authors evaluated whether response to neoadjuvant chemotherapy was correlated with the molecular classification groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Using immunohistochemistry, the molecular classification group (luminal\u2010A, luminal\u2010B, HER\u20102\u2013variant, HER\u20102\u2013classic, and basal phenotype) was retrospectively determined in 68 breast cancer patients who received neoadjuvant treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>A total of 28 carcinoma patients (41.2%) achieved a compete pathologic response (CPR), including 2 of 15 patients classified as having luminal\u2010A (13.3%), 4 of 16 patients classified as having luminal\u2010B (25.0%), 10 of 12 patients classified as having HER\u20102\u2013classic (83.3%), none of the 4 patients classified as having HER\u20102\u2013variant, and 12 of 21 patients classified as having basal phenotype (57.1%) neoplasms. The CPR rate among patients with the HER\u20102\u2013classic and basal neoplasms was 67% (22 of 33 neoplasms), compared with 17.1% (6 of 35 neoplasms) in the non\u2010HER\u20102\u2013classic\/basal combined group (<jats:italic>P<\/jats:italic> &lt; .001). Eleven carcinomas were initially diagnosed as invasive lobular carcinomas (pleomorphic and classic), 4 of which were luminal\u2010A, 4 of which were luminal\u2010B, 2 of which were HER\u20102\u2013classic, and 1 of which was basal. On review, only 3 of these 11 cases remained classified as classic lobular carcinoma, all of which were classified as luminal\u2010A, and none of these patients achieved a CPR. Four of the other 8 patients achieved a CPR.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>The molecular classification system is useful for identifying carcinoma patients who are most likely and those who are least likely to achieve a CPR. In the current study, all the morphologically classic lobular carcinomas were classified as luminal\u2010A neoplasms, which may explain the low rate of CPR reported. Cancer 2007. \u00a9 2007 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.22981","type":"journal-article","created":{"date-parts":[[2007,8,24]],"date-time":"2007-08-24T21:53:40Z","timestamp":1187992420000},"page":"1687-1696","source":"Crossref","is-referenced-by-count":79,"title":["Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy"],"prefix":"10.1002","volume":"110","author":[{"given":"Neal S.","family":"Goldstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Severson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Schell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Vicini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayana S.","family":"Dekhne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,9,19]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.7.1558"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00212-0"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02303848"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22177"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2672"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.460"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1304"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.005"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.032"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.7.2483"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21070"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.232"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2002.s.015"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.09.056"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02968293"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-005-9008-8"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/028418699431186"},{"key":"e_1_2_5_19_2","first-page":"955","article-title":"Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response","volume":"9","author":"Davis DW","year":"2003","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg449"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197806012982203"},{"key":"e_1_2_5_22_2","first-page":"37","article-title":"NSABP Protocol B\u201327. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel","volume":"11","author":"Mamounas EP","year":"1997","journal-title":"Oncology (Williston Park)."},{"key":"e_1_2_5_23_2","first-page":"7","article-title":"Docetaxel (Taxotere) plus doxorubicin\u2013based combinations: the evidence of activity in breast cancer","volume":"26","author":"Nabholtz JM","year":"1999","journal-title":"Semin Oncol."},{"key":"e_1_2_5_24_2","first-page":"1319","article-title":"Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome","volume":"22","author":"Penault\u2013Llorca F","year":"2003","journal-title":"Int J Oncol."},{"key":"e_1_2_5_25_2","first-page":"124","article-title":"A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer","volume":"9","author":"Stearns V","year":"2003","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/35021093"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191367098"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.08.021"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-7-127"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20366"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0932692100"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409462102"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0763"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.767.65.3"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0429"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0220"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21004"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4"},{"key":"e_1_2_5_39_2","first-page":"9","volume-title":"Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs","author":"World Health Organization","year":"2003"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1991.tb00229.x"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(75)80099-2"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1979.tb03029.x"},{"key":"e_1_2_5_43_2","first-page":"74","article-title":"A histologic classification of carcinoma of the breast","volume":"19","author":"Foote FW","year":"1946","journal-title":"Surgery."},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200012000-00009"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(92)90321-S"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000152138.89395.fb"},{"key":"e_1_2_5_47_2","first-page":"155","article-title":"Prognostic and predictive factors in breast cancer by immunohistochemical analysis","volume":"11","author":"Allred DC","year":"1998","journal-title":"Mod Pathol."},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602184"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1559"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800255"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800445"},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.08.015"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1916"},{"key":"e_1_2_5_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.6.1456"},{"key":"e_1_2_5_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.005"},{"key":"e_1_2_5_56_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0380"},{"key":"e_1_2_5_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11245"},{"key":"e_1_2_5_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052122"},{"key":"e_1_2_5_59_2","doi-asserted-by":"publisher","DOI":"10.1053\/ejso.2002.1404"},{"key":"e_1_2_5_60_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.111"},{"key":"e_1_2_5_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.08.015"},{"key":"e_1_2_5_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20491"},{"key":"e_1_2_5_63_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl114"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22981","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:21:56Z","timestamp":1760296916000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,19]]},"references-count":62,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,10,15]]}},"alternative-id":["10.1002\/cncr.22981"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22981","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,19]]}}}